Click here to submit Post PR News
Siemens and Merck drive forward modular production in industry
Siemens and science and technology company Merck will work together in future at Merck’s headquarters in Darmstadt to develop a technical backbone for the modular production of the future. The aim is to create a production line that flexibly combines →
Views : 2267
US biopharma innovation can be harmed by ongoing trade war with China
The ongoing trade war between the US and China will have huge ramifications on the biopharmaceutical industry for both countries. However, it seems that China is in a much well position from a negotiation viewpoint, according to leading data and →
Views : 1081
Age-related macular degeneration market will rise to $11.5 billion by 2026
Pharmaceutical sales for age-related macular degeneration (AMD) marketplaces were projected to be $4.9 billion in 2016, and it’s expected to reach a price of $11.5 billion in 2026, with a Compound Annual Growth Rate (CAGR) rise of 8.9%, stated by →
Views : 865
Multiple Sclerosis (MS) Growth to Reach $25.3 billion in 2026, at a CAGR of 2.9%
March 3, 2018 Healthcare: In 2016, Multiple Sclerosis (MS) disease-modifying therapies (DMTs) sales were expected to be $19.1 billion across the seven major markets (7MM*) in 2016. This continues to grow to $25.3 billion in 2026, at a CAGR of →
Views : 1099
Review Osteoarthritis Global Clinical Trials
June 6, 2017 This report provides top line data relating to the clinical trials on Osteoarthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease →
Views : 1209
The Risk Factors and Global Trends of Bladder Cancer – Epidemiology
June 6, 2017 Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide. The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These →
Views : 1113
Acute Myeloid (Myelogenous, Myelocytic) Leukemia (AML) Will Increase By Almost Three-Fold Reaching $932 Million In 2024 At A CAGR Of 10.5%.
June 6, 2017 Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. →
Views : 1045
